OKYO Pharma has filed a Fast Track designation application with the Food and Drug Administration (FDA) for urcosimod in the treatment of neuropathic ...
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
Variation in CGM bias by postprandial test, with glycemic index for commercial fruit smoothie higher with CGM versus capillary sampling ...
Lorundrostat is an orally-administered highly selective aldosterone synthase inhibitor that reduces aldosterone levels by inhibiting CYP11B2. The Launch-HTN trial (ClinicalTrials.gov Identifier: ...
Researchers found no significant change in the prevalence of diabetes, from 12.8% in 2013-2014 to 14.1% in 2021-2023.
Death marks second fatality in growing outbreak, following the death of an unvaccinated school-aged child in Texas.
Physicians overall have higher odds of depressed mood and mental health, job, and legal problems preceding suicide ...
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback